Fasting rules assume the stomach empties on schedule. On GLP-1s it may not. New UK data put regurgitation risk at 11 times baseline — and anaesthetists say patients keep it secret.
In October, anaesthetists in Australia and New Zealand did something unusual: they published a warning aimed not at doctors but at patients. If you inject a GLP-1 drug or any weight-loss peptide, the Australian and New Zealand College of Anaesthetists (ANZCA) said, tell your anaesthetist before you go under. The concern is not the weight loss. It is that your stomach may still contain food even though you followed every fasting rule in the letter.
Standard fasting advice — no solids for six hours, clear fluids until two — rests on one assumption: a healthy stomach empties itself on a predictable clock. GLP-1 drugs slow that clock. The instructions everyone treats as universal quietly stop working for the fastest-growing group of surgical patients. In the UK study that triggered the warning, 1 in 36 people arriving for anaesthesia was on a GLP-1. Peri-operative management of those patients was, in the researchers' own word, variable.
Published in the journal Anaesthesia in September 2026, it is the largest look at this question so far: 47,039 patients across 119 UK hospitals, screened prospectively for GLP-1 use in the three months before their procedure. Of those, 1,348 (2.9%) were taking one.
The headline number: regurgitation or pulmonary aspiration — stomach contents coming back up, or reaching the lungs — occurred in 19 of 1,348 GLP-1 patients (1.41%), against 57 of 45,691 everyone else (0.12%). That is an odds ratio of 11.39. In plain language, about 1 in 71 GLP-1 patients versus 1 in 802. Most events happened during emergence from anaesthesia, when protective reflexes switch back on in a disordered way and a full stomach is most likely to make a reappearance.
Two caveats the authors raise themselves. First, the absolute risk stays small: 1.4% still means a 98.6% chance of nothing happening. Second, this is an association, not proof of cause — people with obesity and type 2 diabetes already carry higher baseline aspiration risk, and the study cannot fully separate the drug from the conditions it treats. What it does show is that following the standard fasting rules did not neutralise the risk.
Science being science, the second-biggest dataset points partly the other way. A target-trial emulation published in the American Journal of Medicine in October 2026 matched 21,948 anaesthesia patients in a multinational database and found GLP-1 users had fewer pulmonary complications overall (hazard ratio 0.68), with a small increase in gastrointestinal events (1.03). A September systematic review in Cureus covering 16 studies landed in between: residual stomach contents on ultrasound and endoscopy were consistently higher in GLP-1 users despite proper fasting, but clinically apparent aspiration remained rare, and larger observational studies did not show a clear increase. Our earlier reporting on what peptide-vial testing actually found covers a different problem — what is in the vial — but the theme rhymes: the label tells you less than you think.
How to hold both truths: GLP-1s reliably change gastric physiology — food demonstrably stays longer — while the downstream catastrophe stays uncommon and its true size is genuinely uncertain. The disagreement is about how much protection modern anaesthesia provides, not about whether the stomach slows. That is why the conversation has moved from the drug to the plan.
For about two years the standard advice was simple: skip your GLP-1 dose before surgery. That consensus has largely reversed. A comparative review of five major international guidelines published since 2023 (Saudi Journal of Anaesthesia, October 2026) found that four of five now recommend continuing the drug and changing the fasting plan instead — superseding the 2023 American Society of Anesthesiologists pause-first policy.
Three reasons explain the flip. One: nobody has shown that stopping the drug actually empties the stomach in time. Professor Michael Horowitz, a gastrointestinal physiologist at the University of Adelaide, called the one-week pause "demonstrably stupid" in an ABC News interview — slowed gastric emptying can persist well past the last dose. Two: pausing is not harmless. In someone using a GLP-1 to control type 2 diabetes, a forced break destabilises glucose control exactly when surgical stress hits, and it may cost cardiorenal benefits. Three: the alternative works on paper — modify the fasting instead of the medication.
The protocols differ in detail but converge on the shape. ANZCA's current recommendation is 24 hours of clear fluids followed by the standard six-hour solid-food fast. The Korean Society of Anaesthesiologists' 2026 consensus says much the same and adds bedside gastric ultrasound when delayed emptying is suspected. Which brings up the tool everyone endorses and nobody has validated: all five guidelines support pre-anaesthetic gastric ultrasound, and not one defines a decision threshold for acting on it. It can show whether your stomach is empty. What to do with "not empty" remains clinician judgement — the gap the next generation of studies has to close.
ANZCA's president, Dr Tanya Selak, gave ABC News the reason this warning exists at all: patients are not disclosing. Some forget. Some are embarrassed — she calls it weight stigma, the fear of being judged or treated differently. Some are hiding an unapproved peptide bought online and injected without medical supervision: "a peptide injection someone gave me at the gym," as she put it. Australia's regulator has since announced compliance measures targeting suppliers of unapproved products after a run of harm cases, including a reported torn oesophagus linked to unapproved retatrutide use.
Here is the blunt version. Your anaesthetist is not going to report you, shame you, or cancel your surgery for sport. They need to know exactly what you took, when you last took it, and why — because the fasting instructions, the airway plan, and the decision to proceed all change with it. A patient who conceals their GLP-1 and follows standard fasting has chosen the worst of both worlds: exposed to the residual-stomach risk while denying the team any chance to mitigate it.
Do not stop your GLP-1 on your own. That is the one instruction every source agrees on — stopping is a medical decision, not a pre-op hack.
Tell the surgical and anaesthesia team everything: GLP-1s, compounded versions, research peptides, gym-source injections. Include the date of your last dose and the reason you take it.
Expect a different fasting rule. If they follow ANZCA or similar guidance, it will look like a 24-hour clear-liquid diet plus the standard six-hour fast for solids — longer and stricter than the sheet the next patient got.
Ask what their plan is. Reasonable questions: do you modify fasting for GLP-1s? Do you use gastric ultrasound? If my stomach isn't empty, is the plan to delay, to proceed with airway protection, or something else?
If you use unapproved or grey-market peptides, say so anyway. The disclosure is protected health information. The surprise during emergence is not.
Evidence grade: B. A large prospective multicentre cohort (n=47,039) supports an approximately 11-fold relative increase in regurgitation or aspiration among GLP-1 users, but a matched multinational analysis (n=21,948) found no increase in pulmonary complications, and a 16-study review finds the physiological effect consistent while clinical events stay rare. Guidelines converge on disclosure and modified fasting; the causal question remains open.
Medical disclaimer: This article is educational and is not medical advice. Perioperative decisions belong to your surgical and anaesthesia team — tell them every medication and supplement you take and follow their instructions. Oria exists to make the evidence around peptides and peptide-adjacent drugs readable, sourced, and honest about what is not yet known; nothing here should change a treatment plan without a clinician who knows your history.
